Thinly traded micro cap Verastem slumps 54% in premarket trading on robust volume in response to its announcement that has terminated its Phase 2 clinical trial of lead product candidate VS-6063 in mesothelioma after an interim analysis failed to identify a sufficient level of efficacy to justify moving forward.
